H.R. 427 · 118th Congress · Health

SAVE Moms and Babies Act of 2023

Died in committee974 words Introduced Jan 20, 2023 · Latest action Jan 27, 2023

How far it has goneStopped at 2 of 6 · Died in committee
  1. IntroducedJan 20, 2023 Done
  2. CommitteeDied Jan 3, 2025 Stopped here
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.

Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.

The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.

The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)

Congressional Research Service · summary of “Introduced in House” version · Jan 20, 2023

Who lobbies on it

2 organizations · 11 filings · Q1 2023–Q4 2024

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Susan B Anthony List 7 of 8 quarters
    “H.R. 5577, S. 3017 FACE Act Repeal of 2023; S. 2801, H.R. 5492 Veteran Families Health Services Act of 2023; H.R. 8070, S. 4638 Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025; S. 4128, H.R. 8029 VA Abortion Transparency Act of 2024; H.R.26, S. 204 Born-Alive…”

    Q4 2024 filing · $1.2M lobbying spend in 2024, all issues

  2. Students for Life Action 4 of 8 quarters
    “Protecting Life on College Campus Act H.R. 435 Protecting Life on College Campus Act S. 16 Life At Conception Act H.R. 431 Heartbeat Protection Act H.R. 175 Equal Rights Amendment H.J. Res 25 & H.J. Res 4 Women's Health Protection Act H.R. 12 & S. 701 No Taxpayer Funding for Abortion and Abortion Insurance Disclosure…”

    Q4 2024 filing · Under $5,000 lobbying spend in 2024, all issues

Organizations that named H.R. 427 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

3 actions · newest first
  1. Jan 27, 2023Referred to the Subcommittee on Health.
  2. Jan 20, 2023Referred to the House Committee on Energy and Commerce.
  3. Jan 20, 2023Introduced in House